 I. To determine the response rates following treatment with PD 0332991 in the following malignancies: 1 Metastatic breast cancer, 2 Metastatic colorectal cancer, 3 Metastatic melanoma with CDK4 mutation or amplification, or 4 Cisplatin-refractory, unresectable germ cell tumors. 